Management of Multifocal and Multicentric Gliomas

Neurosurgery Clinics of North America

Volumn 23, Issue 2, 2012, Pages 343-350

  Patil, Chirag G ^a   Eboli, Paula ^a   Hu, Jethro ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; Glioma; Multicentric; Multifocal; Treatment

Indexed keywords

ADENOVIRUS VECTOR; ALPHAVBETA5 INTEGRIN; BEVACIZUMAB; CADHERIN; CARBOXYMETHYLCELLULOSE; CILENGITIDE; DASATINIB; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLT3 LIGAND; GEFITINIB; HERMES ANTIGEN; INTEGRIN; MARIMASTAT; MATRIX METALLOPROTEINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD44; MONOCLONAL ANTIBODY DC101; NERVE CELL ADHESION MOLECULE; PLACEBO; POLYLYSINE; RILOTUMUMAB; TEMOZOLOMIDE; TENASCIN; TENASCIN C MONOCLONAL ANTIBODY; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITRONECTIN RECEPTOR;

ADJUVANT THERAPY; BRAIN LYMPHOMA; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STEM CELL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRANIOTOMY; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOSARCOMA; HUMAN; MULTICENTRIC GLIOBLASTOMA; MULTIFOCAL GLIOBLASTOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; REVIEW; STEREOTACTIC BIOPSY; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; TUMOR LOCALIZATION; WHOLE BRAIN RADIOTHERAPY;

BRAIN NEOPLASMS; GLIOMA; HUMANS; NEOPLASMS, MULTIPLE PRIMARY;

EID: 84863366935     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.01.012     Document Type: Review

References (52)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
2. Batzdorf U., Malamud N. The problem of multicentric gliomas. J Neurosurg 1963, 20:122-136.
3. Hassaneen W., Levine N.B., Suki D., et al. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. Clinical article. J Neurosurg 2011, 114:576-584.
4. Hefti M., von Campe G., Schneider C., et al. Multicentric tumor manifestations of high grade gliomas: independent proliferation or hallmark of extensive disease?. Cen Eur Neurosurg 2010, 71:20-25.
5. Jaskolski D., Zawirski M., Wisniewska G., et al. A case of multicentric glioma of cerebellum and brain. Zentralbl Neurochir 1988, 49:124-127.
6. Kato T., Aida T., Abe H., et al. Clinicopathological study of multiple gliomas-report of three cases. Neurol Med Chir (Tokyo) 1990, 30:604-609.
7. Salvati M., Caroli E., Orlando E.R., et al. Multicentric glioma: our experience in 25 patients and critical review of the literature. Neurosurg Rev 2003, 26:275-279.
8. Solomon A., Perret G.E., McCormick W.F. Multicentric gliomas of the cerebral and cerebellar hemispheres. Case report. J Neurosurg 1969, 31:87-93.
9. Chamberlain M.C. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011, 101:319-323.
10. Silbergeld D.L., Rostomily R.C., Alvord E.C. The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults. J Neurooncol 1991, 10:179-185.
11. Kyritsis A.P., Levin V.A., Yung W.K., et al. Imaging patterns of multifocal gliomas. Eur J Radiol 1993, 16:163-170.
12. Bradley W.L. Case of gliosarcomatous tumors of the brain. Proc Conn Med Soc 1880, 2:39-41.
13. Willis R.A. Pathology of tumors 1960, Butterworths, London, p. 811.
14. Ampil F., Burton G.V., Gonzalez-Toledo E., et al. Do we need whole brain irradiation in multifocal or multicentric high-grade cerebral gliomas? Review of cases and the literature. J Neurooncol 2007, 85:353-355.
15. Claes A., Idema A.J., Wesseling P. Diffuse glioma growth: a guerilla war. Acta Neuropathol 2007, 114:443-458.
16. Kyritsis A.P., Bondy M.L., Xiao M., et al. Germline p53 gene mutations in subsets of glioma patients. J Natl Cancer Inst 1994, 86:344-349.
17. Kyritsis A.P., Yung W.K., Leeds N.E., et al. Multifocal cerebral gliomas associated with secondary malignancies. Lancet 1992, 339:1229-1230.
18. Scherer H. Structural development in gliomas. Am J Cancer 1938, 34:333-351.
19. Geer C.P., Grossman S.A. Interstitial fluid flow along white matter tracts: a potentially important mechanism for the dissemination of primary brain tumors. J Neurooncol 1997, 32:193-201.
20. Bassoe P. Multiple ependymal glioma-one tumor of the fourth ventricle, the other of the frontal lobes. Arch Intern Med 1908, 2:194-200.
21. Salunke P., Badhe P., Sharma A. Cerebellar glioblastoma multiforme with non-contiguous grade 2 astrocytoma of the temporal lobe in the same individual. Neurol India 2010, 58:651-653.
22. Chadduck W.M., Roycroft D., Brown M.W. Multicentric glioma as a cause of multiple cerebral lesions. Neurosurgery 1983, 13:170-175.
23. Mishra H.B., Haran R.P., Singh J.P., et al. Multicentric gliomas: two case reports and a review of the literature. Br J Neurosurg 1990, 4:535-539.
24. Wang S., Kim S., Chawla S., et al. Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage 2009, 44:653-660.
25. Wang S., Kim S., Chawla S., et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2011, 32:507-514.
26. Marshall L.F., Jennett B., Langfitt T.W. Needle biopsy for the diagnosis of malignant glioma. JAMA 1974, 228:1417-1418.
27. Showalter T.N., Andrel J., Andrews D.W., et al. Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 2007, 69:820-824.
28. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
29. Pouratian N., Crowley R.W., Sherman J.H., et al. Gamma Knife radiosurgery after radiation therapy as an adjunctive treatment for glioblastoma. J Neurooncol 2009, 94:409-418.
30. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60:853-860.
31. Elliott R.E., Parker E.C., Rush S.C., et al. Efficacy of gamma knife radiosurgery for small-volume recurrent malignant gliomas after initial radical resection. World Neurosurg 2011, 76:128-140. [discussion: 161-2].
32. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
33. Hegi M.E., Liu L., Herman J.G., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
34. Pardridge W.M. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003, 3:90-105. 151.
35. Merzak A., McCrea S., Koocheckpour S., et al. Control of human glioma cell growth, migration and invasion in vitro by transforming growth factor beta 1. Br J Cancer 1994, 70:199-203.
36. McDonough W., Tran N., Giese A., et al. Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. J Neuropathol Exp Neurol 1998, 57:449-455.
37. Schiffer D., Cavalla P., Dutto A., et al. Cell proliferation and invasion in malignant gliomas. Anticancer Res 1997, 17:61-69.
38. Kunkel P., Ulbricht U., Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
39. Norden A.D., Young G.S., Setayesh K., et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008, 70:779-787.
40. Iwamoto F.M., Abrey L.E., Beal K., et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009, 73:1200-1206.
41. Wick A., Dörner N., Schäfer N., et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 2011, 69:586-592.
42. Gunia S., Hussein S., Radu D.L., et al. CD44s-targeted treatment with monoclonal antibody blocks intracerebral invasion and growth of 9L gliosarcoma. Clin Exp Metastasis 1999, 17:221-230.
43. Levin V.A., Phuphanich S., Yung W.K., et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006, 78:295-302.
44. Liu T.J., LaFortune T., Honda T., et al. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol Cancer Ther 2007, 6:357-1367.
45. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005, 353:2012-2024.
46. Lu-Emerson C., Norden A.D., Drappatz J., et al. Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure. J Neurooncol 2011, 104:287-291.
47. Wen P.Y., Schiff D., Cloughesy T.F., et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol 2011, 13:437-446.
48. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
49. Glantz M., Kesari S., Recht L., et al. Understanding the origins of gliomas and developing novel therapies: cerebrospinal fluid and subventricular zone interplay. Semin Oncol 2009, 36:S17-S24.
50. Lim D.A., Cha S., Mayo M.C., et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 2007, 9:424-429.
51. Eyler C.E., Wu Q., Yan K., et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011, 146:53-66.
52. King G.D., Muhammad A.K., Curtin J.F., et al. Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 2008, 10:19-31.